Candel Therapeutics publishes corporate presentation on viral immunotherapies for solid tumors

• Candel highlighted positive Phase 3 data for lead asset aglatimagene besadenovec (CAN-2409) in localized, intermediate- to high-risk prostate cancer, with disease-free survival as primary endpoint in a 745-patient randomized trial.
• Program also showed positive overall survival signals in randomized Phase 2a studies in borderline resectable pancreatic cancer, therapy-resistant non-small cell lung cancer.
• Regulatory positioning includes FDA RMAT designation for CAN-2409 in prostate cancer, Fast Track designations in prostate cancer, NSCLC, pancreatic cancer.
• Balance sheet update cited cash and cash equivalents of $119.7 million as of Dec. 31, 2025, with expected runway into Q1 2028 including proceeds from a February 2026 follow-on equity offering.
• Financing included term loan facility with Trinity Capital of up to $130 million, royalty funding agreement with RTW Investments for $100 million tied to potential approval of CAN-2409 in localized prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on April 14, 2026, and is solely responsible for the information contained therein.